These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 8766645)

  • 1. [Treatment of hypertension in renal parenchymal diseases].
    Iversen BM; Kvam FI; Svarstad E
    Tidsskr Nor Laegeforen; 1996 Jun; 116(17):2022-6. PubMed ID: 8766645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal protection in essential hypertension: how do angiotensin-converting enzyme inhibitors compare with calcium antagonists?
    Bauer JH; Reams GP
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S80-7. PubMed ID: 16989071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Are all antihypertensive drugs renoprotective?].
    Wolf S; Risler T
    Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
    Esnault VL; Brown EA; Apetrei E; Bagon J; Calvo C; DeChatel R; Holdaas H; Krcmery S; Kobalava Z;
    Clin Ther; 2008 Mar; 30(3):482-98. PubMed ID: 18405787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin-converting enzyme inhibition and renal protection. An assessment of implications for therapy.
    Hollenberg NK; Raij L
    Arch Intern Med; 1993 Nov; 153(21):2426-35. PubMed ID: 8215747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized and double-blind comparison of isradipine and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure and hypertension.
    Petersen LJ; Petersen JR; Talleruphuus U; Møller ML; Ladefoged SD; Mehlsen J; Jensen HA
    Clin Nephrol; 2001 May; 55(5):375-83. PubMed ID: 11393383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial.
    Minutolo R; Gabbai FB; Borrelli S; Scigliano R; Trucillo P; Baldanza D; Laurino S; Mascia S; Conte G; De Nicola L
    Am J Kidney Dis; 2007 Dec; 50(6):908-17. PubMed ID: 18037091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihypertensive treatment and glomerular size selectivity in hypertensive patients with renal parenchymal disease and proteinuria.
    Shand BI; Lewis JG; Elder PA; Agarwal M
    Clin Nephrol; 2002 Oct; 58(4):321-4. PubMed ID: 12400851
    [No Abstract]   [Full Text] [Related]  

  • 9. [Angiotensin II type-1-receptor antagonists from the viewpoint of nephrology].
    Hauser AC; Hörl WH
    Wien Med Wochenschr; 2001; 151(7-8):160-4. PubMed ID: 11450164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypertension with co-existing renal disease.
    Bauer JH; Reams GP
    J Hum Hypertens; 1990 Dec; 4 Suppl 5():27-34. PubMed ID: 2090835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal haemodynamic and protective effects of calcium antagonists in hypertension.
    Zanchi A; Brunner HR; Waeber B; Burnier M
    J Hypertens; 1995 Dec; 13(12 Pt 1):1363-75. PubMed ID: 8866898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal protection with calcium antagonism in essential hypertension.
    Bauer JH; Reams GP
    Clin Invest Med; 1989 Oct; 12(5):300-4. PubMed ID: 2689026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the effects of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade on the evolution of spontaneous glomerular injury in male MWF/Ztm rats.
    Remuzzi A; Malanchini B; Battaglia C; Bertani T; Remuzzi G
    Exp Nephrol; 1996; 4(1):19-25. PubMed ID: 8788596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of hypertension in chronic kidney disease.
    Toto RD
    Semin Nephrol; 2005 Nov; 25(6):435-9. PubMed ID: 16298269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of dihydropyridine calcium antagonists in hypertensive patients with impaired renal function.
    Hansson LH
    J Cardiovasc Pharmacol; 1989; 14 Suppl 10():S36-9; discussion S59-62. PubMed ID: 2483570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiorenal protective effects of year-long antihypertensive therapy with an angiotensin-converting enzyme inhibitor or a calcium channel blocker in spontaneously hypertensive rats.
    Ishimitsu T; Honda T; Ohta S; Akashiba A; Takahashi T; Kameda T; Yoshii M; Minami J; Takahashi M; Ono H; Matsuoka H
    Am J Hypertens; 2006 Dec; 19(12):1233-40. PubMed ID: 17161768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of renin-angiotensin to calcium channel blockade in renal disease.
    Tikkanen I; Johnston CI
    Kidney Int Suppl; 1997 Dec; 63():S19-22. PubMed ID: 9407414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline?
    van Essen GG; Apperloo AJ; Rensma PL; Stegeman CA; Sluiter WJ; de Zeeuw D; de Jong PE
    Kidney Int Suppl; 1997 Dec; 63():S58-62. PubMed ID: 9407423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.